Scholars Central

Conference abstractPublished 6 Oct 2014

Cloning high quality antiviral antibodies from the native human antibody repertoire

Authors: Larry Kauvar

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The native human antibody repertoire has long been recognized as an attractive source of therapeutics, particularly for infectious diseases. In the past, however, it has been a difficult source to exploit due to the limited lifetime of human B-cells ex vivo. Trellis has developed a microscopy based assay platform that overcomes the prior limitations and further adds multiplexing into the primary assay. Superlative antibodies have thereby been discovered for influenza, RSV and CMV. These mAbs are all high affinity (sub-nM) and broadly neutralizing across all clinical strains. Moreover, they have low toxicity risk arising from reactivity to human antigens, and are generally easy to express as recombinant proteins. Coupled to rapid manufacturing technologies under development by others, this platform may allow recovery and scale up of countermeasures to emerging pathogens in a time frame suitable to stop an epidemic.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Antivirals & Antiretrovirals
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Larry Kauvar”